Advances at the interface between metabolism & epigenetics 16-17 January, 2019
Robinson College, Cambridge
In partnership with
Advances at the interface between metabolism & epigenetics
Cambridge, January 16-17 2019
Our sponsors and exhibitors
This conference is supported by the Cambridge Metabolic Network, working in partnership with the Babraham Institute, with additional funding from the following sponsors and exhibitors.
2 Advances at the interface between metabolism & epigenetics Cambridge, January 16-17 2019
CONTENTS A few practicalities 5 Optional sessions 5 Day 1 programme 6 Day 2 Programme 8 Link to conference abstracts 9 Contributor biographies 10
3 Full p sponsor ad— HMT
4 Advances at the interface between metabolism & epigenetics Cambridge, January 16-17 2019
A few practicalities
Your badge… is from Blendology.com and uses patented OneTAP technology, making it easy to swap contact details with other conference participants. Tapping badges means that you agree to pass on your name, job title, affiliation and email address plus any other information you might have added to your profile. You can also use your badge to vote for your favourite poster during the conference. If you have any questions about your badge the reception team will be happy to help. Conference dinner… Selwyn College is just a short walk from Robinson College. When you get out onto Grange Road, just turn right and it’s 250m along, on the left. Tea and coffee will be available after the talks on day 1 for anyone who’d like to go straight from one venue to the next, or there’s a little time in case you’d prefer to return to your hotel to freshen up. If you’re not sure whether or not your ticket includes entrance to the conference dinner, please ask at the reception desk. Attendance certificates… we haven’t pre-printed these as we know that not everybody wants them and we don’t want to waste paper. If you would like one, please leave your name at the reception desk and we’ll be happy to provide one for you. We value your feedback… once the conference closes you’ll receive a request from us to complete a short online questionnaire. We’d really appreciate it if you take the time to fill it in as it’s important to us to understand your views and will give us useful information to report back to our funders.
Wednesday 16th January, 13:25 Optional sessions
Drugging Transcription: Progress and Potential for Treating Human Diseases - Cancer, Immunology & Metabolism (Auditorium). Rab Prinjha, VP Head of Epigenetics DPU for GSK, will talk about current research interests. No need to book. Meet the speaker (Auditorium Lounge) Prof Paulo Sassone-Corsi and Dr Sevin Turcan will be available for an informal chat over coffee. Places are limited, please book in advance. Thursday 17th January, 12:40
Alternatives to an academic career: why I took a different path (Auditorium) Do you know what you want to achieve in your career? Are you familiar with all the opportunities for someone with a research background? In the UK, just over half of new PhD graduates move out of higher education, taking their skills into the wider economy [What do researchers do? www.vitae.ac.uk]. 75% of those who remain aspire to an academic career but many are not aware of the breadth of opportunities open to them [Careers in Research Online Survey, www.vitae.ac.uk]. Our panel, Dr Rab Prinjha, VP Head of Epigenetics DPU for GSK, Dr Marc van der Schee, Head of Clinical at Owlstone Medical and Dr Daniel Ives, CEO of early stage start-up Shift Bioscience will offer insights based on their experience of research in non-academic settings. A great opportunity to put your questions to them. No need to book. Meet the speaker (Auditorium Lounge) Dr Andrew Pospisilik and Dr Erica Watson will be available for an informal chat over coffee. Places are limited, please book in advance.
5 Advances at the interface between metabolism & epigenetics Cambridge, January 16-17 2019
Programme, day 1 - Wednesday 16th January 2019
08:45 Registration opens Dining hall balcony, dining hall Exhibition; refreshments
09:30 Prof Patrick Maxwell Welcome & introduction Auditorium Regius Professor of Physic & Head of the
School of Clinical Medicine, University of Cambridge
SESSION 1 Epigenetic responses to metabolic and environmental changes Auditorium Session chair: Prof Brian Huntly
09:40 Prof Paolo Sassone-Corsi KEYNOTE Donald Bren Professor & Director of the The epigenetic language of circadian metabolism Center for Epigenetics & Metabolism, University of California, Irvine 10:40 Prof Jane Mellor Deconstructing the relationship between Department of Biochemistry, metabolism, chromatin & gene expression in the University of Oxford yeast metabolic cycle
11:10 Break for refreshments Dining hall Exhibition
11:45 Prof Andrew Pospisilik Epigenetic contributions to metabolic disease Max Planck Institute of Immunobiology & heterogeneity Epigenetics, Freiburg & Van Andel Research
Institute, Grand Rapids 12:15 Dr Marcus Buschbeck Histone variants link metabolism to 3D chromatin Josep Carreras Leukaemia Research Institute, architecture Barcelona
12:30 Poster previews Auditorium
Elena Stoyanova Deciphering a metabolism-sensitive readout of Babraham Institute, Cambridge histone crotonylation Dr Philip Bland MLL3 mutations overcome glycolytic stress in Institute of Cancer Research, London breast cancer by utilising the pentose phosphate pathway Matthew Sinton Intracellular lipid accumulation in hepatocytes University of Edinburgh leads to dysregulation of the TCA cycle & a global increase in 5-hydroxymethylcytosine Dr Simone Ecker Epigenetics of exceptional longevity UCL Cancer Institute, London
6 Advances at the interface between metabolism & epigenetics Cambridge, January 16-17 2019
Cont...
12:45 Break for lunch Exhibition; ‘Meet the speaker’ tables Dining hall; Auditorium lounge 13:25 Optional session: Dr Rab Prinjha Drugging Transcription: Progress and Potential for VP Head of Epigenetics DPU, GSK Treating Human Diseases- Cancer, Immunology & Metabolism Auditorium 13:45 Poster session opens Browse abstracts at www.metabolism.ac.uk/EpiMetAbstracts Please cast your vote using your OneTAP badge Dining hall
SESSION 2 Metabolic control of epigenetic pathways Auditorium Session chair: Dr Jason Locasale
15:10 Prof Wolfgang Fischle Lipid precursors & lipids in chromatin regulation King Abdullah University, Saudi Arabia
15:40 Dr Kathryn Wellen Acetyl-CoA metabolism in chromatin regulation Department of Cancer Biology, University of & tumorigenesis Pennsylvania
16:10 Mattia Zaghi SETD5, a new connection between epigenetic & Vita-Salute San Raffaele university mitochondrial function
16:25 Break for refreshments Exhibition Dining hall
17:00 Dr Thomas Carell Ludwig Maximilian University of Munich Metabolic control of Tet activity in the brain
17:30 Dr Andreas Ladurner Allosteric activation of a chromatin remodelling Ludwig Maximilian University of Munich oncogene by NAD metabolites
You may either hold onto your OneTAP badge overnight or return it to us & collect it in the morning
18:45 Drinks reception & conference dinner Selwyn College, Grange Road, Cambridge
7 Advances at the interface between metabolism & epigenetics Cambridge, January 16-17 2019
Programme, day 2 - Thursday 17th January 2019
08:30 Registration desk opens Dining hall balcony, dining hall Refreshments 09:00 Dr Christian Frezza Welcome to day 2 Auditorium On behalf of the organisers
SESSION 3 Physiological effects on the epigenome Auditorium Session chair: Prof Anne Ferguson-Smith
09:05 Dr Erica Watson How your grandparents’ sins affect your health Department of Physiology, Development & Neuroscience University of Cambridge
09:35 Dr Marika Charalambous Genomic imprinting - adiposity & pregnancy Department of Medical & Molecular Genetics, King’s College London
10:05 Dr Alice Taylor Methionine metabolism impacts maintenance of University of Cambridge AML with chromatin regulation
10:20 Break for refreshments Dining hall Exhibition
10:45 Prof Cecilia Lindgren Epigenomics of common obesity Big Data Institute, University of Oxford
11:15 Dr Olivia Casaneueva Variability in neuronal heat shock responses Babraham Institute, Cambridge causes heterogeneity in fat metabolism across individual worms
11.45 Dr Simona Pedrotti The histone methyltransferases Suv420h regulate PPAR-ɣ & energy expenditure in response to San Raffaele Hospital, Milan environmental stimuli
12:00 Break for lunch Dining Hall; Auditorium Lounge Exhibition; ‘Meet the speaker’ tables 12:40 Optional session: Dr Rab Prinjha, VP Head of Epigenetics DPU, GSK; Alternatives to an academic career: why I took a Dr Marc van der Schee, Owlstone Medical; different path Auditorium Dr Daniel Ives, Shift Bioscience
8 Advances at the interface between metabolism & epigenetics Cambridge, January 16-17 2019
Cont...
SESSION 4 Metabolism and epigenetics in disease Auditorium Session chair: Dr Kathryn Wellen
13:25 Dr Judith Favier Uncoupled effects of TET inhibition & hypoxia in Research Director, Head of the Genetics and SDH-deficient cells
Metabolism of Rare Cancers Laboratory, Inserm, Paris
13:55 Dr Sevin Turcan The impact of IDH1 mutation on the glioma Heidelberg University Hospital epigenome
14:25 Break for refreshments Exhibition Dining hall
14:50 Dr Jason Locasale Duke University, North Carolina Diet, cancer and epigenetics
15:20 Professor Brian Huntly Transcriptional & metabolic alterations during Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge leukaemia evolution
15:50 Professor Sir Stephen O’Rahilly Prizes & closing remarks Head of the University of Cambridge Metabolic Research Laboratories and co-director of the Institute of Metabolic Science
16:00 Close
Please remember to return your OneTAP badge before leaving. Thank you for joining us in Cambridge & wishing you a safe trip home!
Conference abstracts are available online for participants to download:
http://www.metabolism.cam.ac.uk/wp-content/uploads/2018/12/Abstracts_EpiMet19.pdf
9 Advances at the interface between metabolism & epigenetics Cambridge, January 16-17 2019 Invited speakers
Prof Paolo Sassone-Corsi is Donald Bren Professor of Biological Chemistry at the School of Medicine, University of California Irvine and Director of the School’s Center for Epigenetics and Metabolism. The focus of his work is on mechanisms of signal transduction able to modulate nuclear functions including epigenetic control. He has received many awards, including the EMBO Gold Medal, the Charles-Leopold Mayer Prize of the Academie des Sciences (France), and the Ipsen Award for Endocrinology (US).
Prof Jane Mellor has been a Lecturer in the Department of Biochemistry at Oxford University since 1995. She established her research group to focus on gene expression and chromatin and has more recently uncovered links between chromatin, transcription and RNA fate, and between chromatin and metabolism. The group has pioneered understanding of the role of non-coding transcription, demonstrating roles in switching chromosome conformation signatures to coordinate gene expression with metabolism and by altering chromatin. Lately, the group has applied mathematical modelling to uncover fundamental principles of transcription that are beyond the resolution of current experimental techniques. Jane has also contributed to three local spin-out companies: Oxford Biodynamics plc (OBD), Chronos Therapeutics Ltd and Sibelius Natural Products Ltd.
Prof Andrew Pospisilik is a Director at the Van Andel Research Institute Center for Epigenetics, Grand Rapids, MI. His group’s focus is to understand the genetic and epigenetic basis of complex disease and their greatest goal is to understand non-genetic phenotypic variation, the mechanisms by which it emerges and is stabilized, and the impact of such variation on disease. During his time as a postdoc at IMBA in Austria he screened the world’s first transgenic fly RNAi library for novel adult-specific regulators of obesity. This provided a functional genome annotation for adiposity in the fly, and opened multiple new research directions for the field including the identification of hedgehog-signaling as one of the first mammalian signals able to discriminate between white and brown adipose tissue function and development.
Prof Wolfgang Fischle of King Abdullah University of Science and Technology (KAUST) studied biochemistry at the University of Tübingen. For his PhD he joined the laboratory of Eric Verdin at the J.D. Glad- stone Institutes. After post-doctoral work with David Allis at The Rockefeller University, he joined the Max Planck Institute for Biophysical Chemistry in Göttingen in 2006 as research group leader. In 2015 he was appointed Professor of Bioscience at KAUST. His research aims to gain detailed and molecular understanding of fundamental epigenetic processes. In particular, he is investigating how chemical modifications of chromatin are functionally translated in a cellular environment. The focus there is on specialized proteins, RNAs and small cellular signaling molecules (e.g. nuclear phospholipids).
Prof Kathryn Wellen of the University of Pennsylvania received her PhD from Harvard University, where she studied the role of inflammation in metabolic diseases. She performed her postdoctoral work with Dr Craig B Thompson at the University of Pennsylvania, where she identified that histone acetylation is sensitive to the availability of the metabolite acetyl-CoA in mammalian cells. In 2011, Dr Wellen started her lab in Department of Cancer Biology at the University of Pennsylvania. Her lab studies how metabolic alterations in cancer cells impact chromatin modification and gene expression during tumorigenesis, as well as how nutrition impacts gene regulation and the implications of this for metabolic health. Her honors include selection as a Forbeck Scholar and as a Pew Scholar in the Biomedical Sciences. 10 Advances at the interface between metabolism & epigenetics Cambridge, January 16-17 2019 Invited speakers cont.
Prof Thomas Carell has been full professor of Organic Chemistry at the Ludwig Maximilians University (LMU) in Munich since 2004. His academic career began at the Universities of Münster and Heidelberg and he obtained his doctorate with Prof. H. A. Staab at the Max-Planck-Institute of Medical Research. After postdoctoral training at MIT he moved to ETH Zürich and then to the Philipps University of Marburg. His group’s research is centred around the Chemical Biology of Nucle- ic Acids, with a special interest in RNA and DNA modifications, including regulatory/ epigenetic modifications as well as detrimental DNA lesions and their repair. An additional research focus is synthetic modifications. The Carell group has developed sophisticated iso- topically labelled nucleosides as tools for DNA and RNA research.
Dr Andreas Ladurner is Full Professor and Chair of Physiological Chemistry at the Biomedical Center of the Ludwig -Maximilian-University of Munich. He first established his laboratory at EMBL in 2003, following completion of post-doctoral research at UC Berkeley. He conducted his PhD in the MRC Centre for Protein Engineering in Cambridge, UK. He has become a leading expert in the identification and analysis of protein modules in epigenetics, centred on the role of cellular metabolites in linking the environment to changes in gene regulation and DNA damage. His current focus is on the role and signalling functions of cellular ADP-ribosylation and his team has pioneered the discovery of the ADP-ribose-sensing macrodomains. By applying knowledge from the fields of transcription and metabolism, his team is dissecting how organisms adapt to nutrients and survive.
Dr Erica Watson is lecturer and group leader in the Department of Physiology, Development and Neuroscience at the University of Cambridge. Her current research aims to understand the epigenetic mechanisms of folic acid metabolism during fetal and placental development and in transgenerational inheritance. She obtained a PhD in developmental biology in 2008 at the University of Calgary and was a Next Generation Fellow at the Centre for Trophoblast Research, University of Cambridge, from 2009-2013. She was awarded the Lister Research Prize in 2015 from the Lister Institute of Preventative Medicine.
Dr Marika Charalambous’ research career has focused primarily on the relationship between epigenetic gene dosage control and developmental physiology. Much of her work has utilised imprinted genes in the mouse as experimental models, since the epigenetic modula- tion of these exquisitely dosage-sensitive genes has important consequences for prenatal growth and development in mouse and man. She started her own group at the Centre for Endocrinology at Queen Mary University of London in early 2013, and recently moved to the Department of Medical and Molecular Genetics at King’s College London.
Professor Cecilia Lindgren is Professor of genomic endocrinology and metabolism at the Nuffield Department of Medicine, Oxford University. She received a PhD in Molecular Genetics from Lund University and was trained in statistical genetics at the Whitehead Institute, MIT during this time. After her post-doctoral work at the Karolinska Institute, she joined the Wellcome Trust Centre for Human Genetics at Oxford. Her research focuses on applying genetics and genomics to dissect the etiology of obesity related traits, with a special focus on fat distribution. Her work has contributed to a substantial furthering of our understanding of the genetic landscape of numerous metabolic traits and in line with this she is co-chair of the GIANT consortium central adiposity team, the obesity working group of UKBBCMC and the quantitative traits team for the GoT2DGenes consortium.
11 Advances at the interface between metabolism & epigenetics Cambridge, January 16-17 2019 Invited speakers cont.
Dr Olivia Casaneueva of the Babraham Institute, Cambridge completed her undergraduate degree in Chile and obtained a PhD at the University of Chicago where she worked with Chip Ferguson in gremlin stem cell maintenance using drosophila as a model organism. She also did two short post-docs, one with Rick Morimto at Northwestern University to work on proteoastasis using C elegans as a model organism and the second with Ben Lehner at CRG in Barcelona, where she worked on the problem of non-genetic influences on proteostasis networks in worms.
Dr Judith Favier is Research Director and Head of the Genetics and Metabolism of Rare Cancers Laboratory at Inserm, Paris. Dr Favier’s lab focuses on pheochromocytomas, paragangliomas and familial cancers associated with mitochondrial dysfunctions. She has a strong interest in mutations in genes encoding TCA cycle enzymes and has specially focused her research on deciphering the mechanisms of metastatic disease associated with SDHB gene mutations. Thanks both to the COMETE network tumors collection and to the unique experimental models generated in her lab, she has made pioneering discoveries in the field, demonstrating the links between succinate dehydrogenase mutations, pseudo-hypoxia, epithelial-to-mesenchymal transition and epigenetic modifications. Judith is a member of the scientific board of the French Endocrine Society, the European Network for the Study of Adrenal Tumors (ENS@T) and the Pheochromocytoma Research Support Organization (PRESSOR).
Dr Jason W Locasale is Associate Professor with tenure at Duke University in the School of Medicine. He graduated from Rutgers University and received his PhD from the Massachusetts Institute of Technology before conducting his postdoctoral training at Harvard Medical School under the mentorship of Lewis Cantley. Dr Locasale has pioneered the use of metabolomics approaches to study cancer biology and metabolism and has made seminal contributions to our understanding of metabolism including the role of serine synthesis in cancers, defining the quantitative, mechanistic principles of the Warburg Effect and altered glucose metabolism in cancer, and the role of metabolism in mediating chromatin status and epigenetics. His research combines quantitative approaches in metabolomics and mathematical modelling with biochemistry, cell biology and genetics.
Dr Sevin Turcan is a Max-Eder junior research group leader at Heidelberg University Hospital. Sevin received her bachelor’s degree in Biomedical Engineering from Johns Hopkins University prior to earning a PhD from Tufts University. She completed her postdoctoral fellowship at Memorial Sloan Kettering Cancer Center in the laboratory of Timothy Chan. Her interests are focused on understanding the molecular determinants that drive gliomagenesis, with a particular focus on IDH mutant gliomas. Her lab uses multiple approaches to investigate the role of oncogenic transcription factors in malignant gliomas and to delineate the role of IDH mutations in glioma epigenetics.
Professor Brian Huntly of the Wellcome-MRC Cambridge Stem Cell Institute studied Medicine at Edinburgh, trained in Haematology in Dundee and Cambridge and did post- doctoral work at Harvard. He is a member of the Royal College of Physicians and a Fellow of the Royal College of Pathologists. His group aims to understand how normal stem and progenitor cell function is subverted during the step-wise evolution of haematological malignancies, particularly acute myeloid leukaemia (AML) and malignant lymphomas, with a particular focus on transcriptional and epigenetic alterations. 12
Advances at the interface between metabolism & epigenetics Cambridge, January 16-17 2019 Speakers chosen from abstracts
Dr Marcus Buschbeck is a group leader at the Josep Carreras Leukaemia Research Institute in Barcelona. His group focusses on the hematopoietic stem cell defects known as myelodysplastic syndromes and the blood cancer myeloid leukemia.
Mattia Zaghi is a PhD student at Vita-Salute San Raffaele university, working under the supervision of Alessandro Sessa in the Stem Cells and Neurogenesis group. His work is focused on understanding the role of different epigenetic cofactors in the pathological process leading to autism and intellectual disabilities, combining in vivo and in vitro models.
Alice V Taylor is a PhD student in the laboratory of Dr Cristina Pina in the University of Cambridge Department of Haematology. She is exploring how modifications in the methionine cycle affect the molecular and cellular characteristics of Acute Myeloid Leukaemia which may be key for a potential drug target.
Dr Simona Pedrotti is a Marie Curie Fellow and postdoctoral researcher in the Gene expression and muscular dystrophy Unit at the San Raffaele Hospital in Milan, which is headed up by Davide Gabellini.
Optional session contributors Dr Rab Prinjha joined GSK from academia. He leads the Epigenetics DPU, cofounded the GSK Biology Council and is a fellow of the Academy of Medical Sciences. Under his leadership the GSK Epigenetics DPU has been responsible for many novel and exciting discoveries in the area of exploring and exploiting epigenetic inhibitors in human disease treatment. His group has already advanced seven novel epigenetic medicines into clinical studies with many more in the pipeline.
Dr Marc van der Schee holds a medical degree and a doctorate in Biomedical Sciences. He obtained his PhD studying the use of volatile biomarkers for disease diagnosis, monitoring and prognosis prediction. He designs and oversees clinical trials within Owlstone Medical helping to collect data that drives product development and implementation into clinical practice. Marc helps prioritise medical applications and is the primary interface between clinical partners and Owlstone.
Dr Daniel Ives is harnessing the epigenetic ageing clock to guide development of drugs that fight fundamental ageing processes. At Cambridge University and later at the Crick Institute he identified small-molecule drugs that eliminate DNA mutations which cause rare mitochondrial disease and are linked to ageing and age-associated diseases. Daniel founded Shift Bioscience to build on this work and commercialise novel therapeutics for ageing and diseases of ageing. 13 NOTES
14 Full page sponsor ad: Biochem soc
15 The Cambridge Metabolic Network links and promotes research activities among the broad academic research community in Cambridge, across all Schools of the University and key regional partner organisations.
Our goal is to generate fresh insight into research in the field of metabolism. We want to establish a multidisciplinary community of researchers, support development of new research, co-ordinate activities in areas of importance to research in metabolism and facilitate translation of research to benefit current and future populations.
www.metabolism.cam.ac.uk
Organisers: Dr Miguel Constancia, Senior Lecturer in Reproductive Biology, University of Cambridge Dr Christian Frezza, Principal Investigator, MRC Cancer Unit University of Cambridge Dr Peter Rugg-Gunn, Principal Investigator, Babraham Institute Dr Jane Sugars, Coordinator, Cambridge Metabolic Network
16